198 related articles for article (PubMed ID: 17486070)
21. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer.
Sunaga N; Miyajima K; Suzuki M; Sato M; White MA; Ramirez RD; Shay JW; Gazdar AF; Minna JD
Cancer Res; 2004 Jun; 64(12):4277-85. PubMed ID: 15205342
[TBL] [Abstract][Full Text] [Related]
22. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
23. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.
Fred RG; Boddeti SK; Lundberg M; Welsh N
Clin Sci (Lond); 2015 Jan; 128(1):17-28. PubMed ID: 24865476
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
[TBL] [Abstract][Full Text] [Related]
27. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.
Imam SZ; Zhou Q; Yamamoto A; Valente AJ; Ali SF; Bains M; Roberts JL; Kahle PJ; Clark RA; Li S
J Neurosci; 2011 Jan; 31(1):157-63. PubMed ID: 21209200
[TBL] [Abstract][Full Text] [Related]
28. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
29. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
30. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo.
Ji L; Nishizaki M; Gao B; Burbee D; Kondo M; Kamibayashi C; Xu K; Yen N; Atkinson EN; Fang B; Lerman MI; Roth JA; Minna JD
Cancer Res; 2002 May; 62(9):2715-20. PubMed ID: 11980673
[TBL] [Abstract][Full Text] [Related]
31. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
33. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
34. Gleevec target Abl important for normal immune activation of T cells.
Cancer Biol Ther; 2004 Aug; 3(8):704. PubMed ID: 15751157
[No Abstract] [Full Text] [Related]
35. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts.
Bujor AM; Asano Y; Haines P; Lafyatis R; Trojanowska M
Arthritis Rheum; 2011 Jun; 63(6):1729-37. PubMed ID: 21321929
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
Alpay K; Farshchian M; Tuomela J; Sandholm J; Aittokallio K; Siljamäki E; Kallio M; Kähäri VM; Hietanen S
PLoS One; 2014; 9(8):e105526. PubMed ID: 25148385
[TBL] [Abstract][Full Text] [Related]
38. c-Abl mediates angiotensin II-induced apoptosis in podocytes.
Chen X; Ren Z; Liang W; Zha D; Liu Y; Chen C; Singhal PC; Ding G
J Mol Histol; 2013 Oct; 44(5):597-608. PubMed ID: 23515840
[TBL] [Abstract][Full Text] [Related]
39. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
[TBL] [Abstract][Full Text] [Related]
40. Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells.
Uno F; Sasaki J; Nishizaki M; Carboni G; Xu K; Atkinson EN; Kondo M; Minna JD; Roth JA; Ji L
Cancer Res; 2004 May; 64(9):2969-76. PubMed ID: 15126327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
